Our scientists have discovered that a migraine medication shows promise in aiding immunotherapy for triple-negative breast cancer.

Triple-negative breast cancer accounts for approximately 15% to 20% of all breast cancer cases and is characterized by high malignancy, low survival rates, and a tendency for recurrence and metastasis within 5 years. The Breast Tumor Center at Fudan University Shanghai Cancer Center, in collaboration with the Fudan University Brain Science Translational Research Institute research team, discovered that sensory nerves within tumors are the “culprits” behind the short-term resistance to immunotherapy in some triple-negative breast cancer patients. They also found that a drug used to treat migraines can enhance sensitivity to immunotherapy. The related findings were published on the 6th in the international academic journal Cell. (Xinhua News Agency)